※ PTMD 2.0 database Online Browse Options

Browse result for Fanconi anemia

※ introduction

    Fanconi anemia (FA) is a rare, autosomal recessive, genetic disease resulting in impaired response to DNA damage in the FA/BRCA pathway. Although it is a very rare disorder, study of this and other bone marrow failure syndromes has improved scientific understanding of the mechanisms of normal bone marrow function and development of cancer. Among those affected, the majority develop cancer, most often acute myelogenous leukemia (AML), MDS, and liver tumors. 90% develop aplastic anemia (the inability to produce blood cells) by age 40. About 60¨C75% have congenital defects, commonly short stature, abnormalities of the skin, arms, head, eyes, kidneys, and ears, and developmental disabilities. Around 75% have some form of endocrine problem, with varying degrees of severity. 60% of FA is FANC-A, 16q24.3, which has later onset bone marrow failure. FA is the result of a genetic defect in a cluster of proteins responsible for DNA repair via homologous recombination. The well-known cancer susceptibility genes BRCA1 and BRCA2 are also examples of FA genes (FANCS and FANCD1 respectively), and biallelic mutation of any of the two genes usually results in an embryonically lethal outcome, and should the proband come to term, experience a severe form of Fanconi anemia. Treatment with androgens and hematopoietic (blood cell) growth factors can help bone marrow failure temporarily, but the long-term treatment is bone marrow transplant if a donor is available. Because of the genetic defect in DNA repair, cells from people with FA are sensitive to drugs that treat cancer by DNA crosslinking, such as mitomycin C. The typical age of death was 30 years in 2000. FA occurs in about one per 130,000 live births, with a higher frequency in Ashkenazi Jews and Afrikaners in South Africa. The disease is named after the Swiss pediatrician who originally described this disorder, Guido Fanconi. Some forms of Fanconi anemia, such as those of complementation group D1, N, and S, are embryonically lethal in most cases, which might account for the rare observation of these complementation groups. It should not be confused with Fanconi syndrome, a kidney disorder also named after Fanconi.

Reference
Wiki: Fanconi anemia



PTMD IDUniProt AccessionEntrez IDGene NameProtein NameOrganism
PTMD01032O152872189
FANCG
Fanconi anemia group G protein
Homo sapiens
PTMD00682Q13761864
RUNX3
Runt-related transcription factor 3
Homo sapiens
PTMD00351P169493925
STMN1
Stathmin
Homo sapiens
PTMD01100P51587675
BRCA2
Breast cancer type 2 susceptibility protein
Homo sapiens
PTMD01237Q9BXW92177
FANCD2
Fanconi anemia group D2 protein
Homo sapiens
PTMD01908Q9NVI155215
FANCI
Fanconi anemia group I protein
Homo sapiens
PTMD02569O153602175
FANCA
Fanconi anemia group A protein
Homo sapiens
PTMD02706O435025889
RAD51C
DNA repair protein RAD51 homolog 3
Homo sapiens
PTMD06078Q005972176
FANCC
Fanconi anemia group C protein
Homo sapiens
PTMD09166Q86Y077444
VRK2
Serine/threonine-protein kinase VRK2
Homo sapiens
PTMD09416Q8IY9284464
SLX4
Structure-specific endonuclease subunit SLX4
Homo sapiens
PTMD09427Q8IYD857697
FANCM
Fanconi anemia group M protein
Homo sapiens
PTMD09706Q8N55492822
ZNF276
Zinc finger protein 276
Homo sapiens
PTMD09916Q8NB912187
FANCB
Fanconi anemia group B protein
Homo sapiens
PTMD12260Q9BX6383990
BRIP1
Fanconi anemia group J protein
Homo sapiens
PTMD13060Q9HB962178
FANCE
Fanconi anemia group E protein
Homo sapiens
PTMD13248Q9NPI82188
FANCF
Fanconi anemia group F protein
Homo sapiens
PTMD13579Q9NW3855120
FANCL
E3 ubiquitin-protein ligase FANCL
Homo sapiens
PTMD14186Q9UI9510459
MAD2L2
Mitotic spindle assembly checkpoint protein MAD2B
Homo sapiens
PTMD01229Q80V6221165
Fancd2
Fanconi anemia group D2 protein homolog
Mus musculus